BioSpace News Archive

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021

Avadel to support AASM Foundation scholarships and training for early career sleep researchers

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc., announces that it has retained Crescendo Communications, LLC as its investor relations firm to help broaden awareness of the Company in the US financial markets.

eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the appointment of Sapna Srivastava, Ph.D., as Chief Financial Officer.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care, today announced it will report results for the fourth quarter and full year 2020 ended January 3, 2021, after the market close on March 18, 2021.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the H.C. Wainwright Global Life Sciences Virtual Conference, taking place March 9-10, 2021.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021.

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

Oncology Pharma Inc. (OTC: ONPH) is pleased to announce initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals.

LLS clinical trials will use the FDA-cleared BioSticker to evaluate correlation of vital signs and select symptoms to treatment [04-March-2021] DENVER , March 4, 2021 /PRNewswire/ -- BioIntelliSense, Inc. , a continuous health monitoring and clinical intelligence company, today announced the company has entered into a strategic partnership with The Leukemia & L